Literature DB >> 15306752

Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: a case study.

Marian P LaMonte1, M J Bernadette Stallmeyer.   

Abstract

BACKGROUND: Direct thrombin inhibitors, a class of anticoagulants distinct from heparins, have not been evaluated for immediate use after thrombolytic therapy in acute ischemic stroke. We report a case of ischemic stroke and prothrombotic state treated using sequenced intravenous and intra-arterial thrombolytic therapy and argatroban anticoagulation. CASE DESCRIPTION: A 19-year-old man with a complicated history of recurrent life-threatening thrombosis presented at the emergency department with acute ischemic stroke. The patient received standard-dose intravenous alteplase starting 2.25 hours after symptom onset without change in his global aphasia and right hemiparesis. Five hours after symptom onset, intra-arterial reteplase was administered for treatment of a left internal carotid "T" occlusion, with successful recanalization of the left internal carotid artery, A1 and M1 segments, and right middle cerebral anterior division and with improvement in symptoms. Argatroban therapy was started after completion of intra-arterial thrombolysis, i.e., 8.5 hours after symptom onset, and was maintained for 14 days. Although the patient sustained a small left basal ganglia infarct, he improved significantly over the course of therapy and was discharged to home without bleeding or further thrombotic episodes.
CONCLUSIONS: Sequenced intravenous and intra-arterial thrombolytic therapy and argatroban anticoagulation was used successfully to safely treat a patient with ischemic stroke and comorbid prothrombotic state within 8.5 hours of symptom onset.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306752     DOI: 10.1023/B:THRO.0000037672.43462.d5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  14 in total

1.  No effect of clot age or thrombolysis on argatroban's inhibition of thrombin.

Authors:  R R Hantgan; W G Jerome; M J Hursting
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

2.  Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis.

Authors:  S Kobayashi; Y Tazaki
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

3.  Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.

Authors:  C A Lewandowski; M Frankel; T A Tomsick; J Broderick; J Frey; W Clark; S Starkman; J Grotta; J Spilker; J Khoury; T Brott
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

4.  Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

Authors:  B E Lewis; D E Wallis; S D Berkowitz; W H Matthai; J Fareed; J M Walenga; J Bartholomew; R Sham; R G Lerner; Z R Zeigler; P K Rustagi; I K Jang; S D Rifkin; J Moran; M J Hursting; J G Kelton
Journal:  Circulation       Date:  2001-04-10       Impact factor: 29.690

5.  Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study.

Authors:  F Vermeer; A Vahanian; P W Fels; P Besse; E Müller; F Van de Werf; D Fitzgerald; H Darius; J Puel; D Garrigou; M L Simoons
Journal:  J Thromb Thrombolysis       Date:  2000-12       Impact factor: 2.300

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

Authors:  Bruce E Lewis; Diane E Wallis; Fred Leya; Marcie J Hursting; John G Kelton
Journal:  Arch Intern Med       Date:  2003 Aug 11-25

Review 8.  Warfarin-induced changes in procoagulant and anticoagulant proteins.

Authors:  Y Stirling
Journal:  Blood Coagul Fibrinolysis       Date:  1995-07       Impact factor: 1.276

9.  Use of intravenous heparin by North American neurologists: do the data matter?

Authors:  Ahmad Al-Sadat; Mohammad Sunbulli; Seemant Chaturvedi
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

10.  Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

Authors:  Bruce E Lewis; William H Matthai; Marc Cohen; Jeffrey W Moses; Marcie J Hursting; Fred Leya
Journal:  Catheter Cardiovasc Interv       Date:  2002-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.